INBX

Inhibrx Biosciences has delivered a strong 1 year share price run, and that kind of move naturally raises the question of whether the current US$97.10 level still lines up with what its book value can support.

Inhibrx Biosciences recently announced that it will present updated data on its clinical-stage candidates INBRX-106 and INBRX-109 from phase 2/3 and phase 2 studies in head and neck squamous cell carcinoma and conventional chondrosarcoma at major oncology and…

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming…

Inhibrx Biosciences' CEO bought $3.6 million in shares after strong Phase 2 data, as insiders accumulate stock amid heavy short interest and an upcoming FDA decision on ozekibart.

Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%.

Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention.

Lappe's purchase through family trusts boosts his beneficial ownership to 950,000 shares, or 6% of outstanding equity, as Inhibrx trades near $114 following a 293% gain over the past year.

Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer.

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.